Evidence map›Paper›PMID 41198055›Full record

ArticleMolecular pharmaceutics2025

Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood-Brain Barrier.

Tobias Gustavsson, Thomas Kustermann, Lars Hvass, Thomas E Wuensche, Anne Skovsbo Clausen, Sophie Stotz, Vladimir Shalgunov, Sara Lopes van den Broek, Gitte M Knudsen, Blanca Aldana and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Tobias GustavssonDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Thomas KustermannPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.
Lars HvassCluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, 2100 Copenhagen Ø, Denmark.ORCID 0000-0003-2048-2409
Thomas E WuenscheDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Anne Skovsbo ClausenCluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, 2100 Copenhagen Ø, Denmark.
Sophie StotzDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.ORCID 0000-0003-4020-1088
Vladimir ShalgunovDepartment of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.ORCID 0000-0001-8956-1207
Sara Lopes van den BroekDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Gitte M KnudsenNeurobiology Research Unit and Institute for Clinical Medicine, Copenhagen University Hospital Rigshospitalet and University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
Blanca AldanaDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Elena FerriDepartment of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125 Modena, Italy.ORCID 0009-0000-0360-8538
Giuseppe CannazzaDepartment of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125 Modena, Italy.ORCID 0000-0002-7347-7315
Jens NiewoehnerPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.
Luca GobbiPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.ORCID 0000-0002-0563-2491
Michael HonerPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.
Umberto Maria BattistiDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.ORCID 0000-0002-1012-8644
Andreas KjaerCluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, 2100 Copenhagen Ø, Denmark.ORCID 0000-0002-2706-5547
Matthias M HerthDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.ORCID 0000-0002-7788-513X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pretargeted PET imaging offers a powerful approach to improve nuclear imaging contrast and reduce systemic radiation exposure, yet its application in the brain has been limited by the blood-brain barrier (BBB). Here, we demonstrate, for the first time, successful pretargeted PET imaging of a brain target enabled by a bispecific antibody engineered for transferrin receptor-mediated BBB transcytosis. By combining this brain shuttle with a novel

Indexed as

Antibodies, MonoclonalBlood-Brain BarrierPositron-Emission TomographyAnimalsAntibodies, BispecificBrainFluorine RadioisotopesHumansMiceRadiopharmaceuticalsReceptors, TransferrinTranscytosisAntibodies, BispecificAntibodies, MonoclonalFluorine RadioisotopesRadiopharmaceuticalsReceptors, Transferrinblood−brain barrierImaging CNSpretargetingtetrazine ligationtransferrin receptor

Identifiers

PMID41198055
PMCPMC12673582

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.